Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
B7-H3.CD28Z.CART in CNS Neoplasms
What the film says
Medulloblastoma and its cousins are the most common malignant brain tumors of childhood. When they return after treatment, there is no reliable cure.
The idea: send engineered immune cells first through the blood, then directly into the fluid around the brain.
Most of these tumors carry a surface protein called B7-H3. A child's own T cells are fitted with a receptor for it, and after chemotherapy makes room, given once by vein. Then, through a small reservoir under the scalp, further doses go into the ventricles every four weeks, up to eight, reaching tumor spread along the brain and spine.
A new trial, at Dana-Farber and Boston Children's, ages two to twenty-one. Susan Chi leads it. Safety first. Public record; not medical advice.
Sources behind this film
Medulloblastoma most common malignant pediatric brain tumor; recurrence has no reliable cure; B7-H3 over-expressed on many tumors; IV infusion on day 0 after Flu/Cy, then intracerebroventricular doses every 28 days up to 8 total; Reservoir under the scalp (Ommaya) (+2 more lines)
The drug
Autologous CAR T cells targeting B7-H3 (CD276), administered intravenously (into the vein) per protocol.
Lymphodepleting chemotherapy administered intravenously per institutional standards.
This is a single-institution, Phase 1/1b, open-label study to test the safety and effectiveness of a cell therapy at different doses for children and young adults with recurrent or progressive brain tumors. Recurrent/recurred means a tumor that has gone away and then came back. This cell therapy is called B7- H3.CD28Z.CART, referred to as B7-H3 CAR T cells. B7-H3 is a protein that is over-expressed on many tumor cells, making it a good target for cancer cell therapy. The U.S.
The study
The purpose of this research study is to test the safety and effectiveness of a cell therapy at different doses for children and young adults with recurrent or progressive brain tumors.
The names of the study investigational therapies involved in this study are: * Fludarabine (a type of chemotherapy) * Cyclophosphamide (a type of chemotherapy) * B7-H3 CAR T cells (a type of cellular therapy)
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.